Ethanol locks for the prevention of catheter-related infection in patients with central venous catheter: A systematic review and meta-analysis of randomized controlled trials


Authors: Jun Zhang aff001;  Bo Wang aff001;  Jinxia Wang aff001;  Qin Yang aff002
Authors place of work: School of Nursing, Gansu University of Chinese Medicine, Lanzhou, Gansu, China aff001;  Department of Special Surgery, the First Hospital of Lanzhou University, Lanzhou, Gansu, China aff002
Published in the journal: PLoS ONE 14(9)
Category: Research Article
doi: 10.1371/journal.pone.0222408

Summary

Background

The widespread use of central venous catheters (CVCs) has exposed patients to a high risk of catheter-related infection (CRI), which is linked to substantial morbidity and mortality. Several strategies for preventing CRI, including ethanol lock prophylaxis, have been explored. This study aimed to provide a comprehensive summary of randomized controlled trials (RCTs) assessing the efficacy and safety of ethanol locks for preventing CRI in patients with CVC.

Methods

We searched six electronic databases, earlier relevant meta-analyses and the reference lists of the included studies for RCTs that assessed the effects of ethanol locks on CRI in patients with CVC versus a control group. Two authors independently assessed the methodological quality of the included studies using the Cochrane Risk of Bias tool and extracted relevant information according to a predesigned extraction form. Data were analyzed using the Cochrane Collaboration’s RevMan 5.3.

Results

Nine studies involving 2451 patients were included. Although limited in power, the results of the meta-analysis indicated a positive effect of ethanol lock prophylaxis on reducing catheter-related bloodstream infection (CRBSI) compared to heparin alone [OR = 0.53, 95% CI 0.34, 0.82, P = 0.004]. The effects on other outcomes, such as exit site infection, catheter dysfunction, catheter removal, thrombosis and mortality, were not statistically significant (P > 0.05). Moreover, although the effect of ethanol on CRBSI was in the expected direction compared to 0.9% NaCl locks, this effect was not statistically significant (P > 0.05).

Conclusions

The present data indicate that ethanol lock prophylaxis is a potential candidate for the prevention of CRBSI in patients with CVC. However, more attention should be paid to the uniform ethanol lock procedure and toxic effects after long-term ethanol lock exposure.

Keywords:

Physical sciences – Chemistry – Chemical compounds – Organic compounds – Alcohols – Ethanol – Organic chemistry – Organic compounds – Alcohols – Ethanol – Mathematics – Statistics – Statistical methods – Metaanalysis – Biology and life sciences – Bioengineering – Biotechnology – Medical devices and equipment – Catheters – Engineering and technology – Bioengineering – Biotechnology – Medical devices and equipment – Catheters – Medicine and health sciences – Medical devices and equipment – Catheters – Pharmacology – Drugs – Heparin – Hematology – Blood coagulation – Coagulation disorders – Thrombosis – Cardiovascular medicine – Cardiovascular diseases – Coagulation disorders – Thrombosis – Vascular medicine – Thrombosis – Nephrology – Medical dialysis – Research and analysis methods – Mathematical and statistical techniques – Statistical methods – Metaanalysis – Research design – Clinical research design – Adverse events – Research assessment – Systematic reviews

Introduction

Central venous catheter (CVC) is an indispensable lifesaving intervention for critically ill adults and pediatric patients requiring treatments such as chemotherapy, parenteral alimentation, hemodialysis and treatment for hematological malignancies. The widespread use of CVC exposes patients to a high risk of catheter-related infection (CRI), which includes catheter-related bloodstream infection (CRBSI) and exit site infection. Despite improved international guidelines on CVC placement and catheter care, CRI remains a major complication. As reported in the literature, 10% to 20% of tunneled catheters become infected in patients receiving chemotherapy for hematological malignancy[1,2]. Among all parenteral nutrition patients, the incidence of CRBSI ranges from 0.6 per 1000 catheter days to 5.36 per 1000 catheter days[3]. Similarly, it has been estimated that the relative risk (RR) for infection in hemodialysis catheters compared with native arteriovenous fistulae is 15.5 and 25.5[4].

CRI can inevitably cause substantial morbidity and mortality, which leads to extended hospital admissions and increased health care costs[5,6]. Thus, preventing CRI is a real clinical challenge, and several strategies have been adopted to reduce its incidence. In recent years, several studies have employed specific locking solutions instead of the standard heparin locks. A promising approach is the use of antibiotic lock solutions for the catheter to prevent intraluminal colonization and the development of biofilm. Decreased CRI rates have been reported by many clinical studies and confirmed in recent meta-analyses[79]. However, concerns have been raised regarding antibiotic lock solutions, given the particular risk of causing microbial resistance, although no substantial evidence has been published to date. Therefore, the preventive use of antibiotics should be avoided if alternative options exist.

For this purpose, ethanol is a potential candidate for the prevention of CRI. It is an easily available antiseptic with a broad antimicrobial spectrum, no known acquired resistance and minimal adverse effects. In the past few years, an increasing number of clinical studies investigating this approach have attested to the benefits of ethanol locks for CRI prevention[1012]. Data from the relevant literature showed that ethanol locks were beneficial for reducing the occurrence of CRI. In addition, a few systematic reviews/meta-analyses regarding this prophylaxis have been published[13,14]. Similarly, these analyses have concluded that ethanol lock solutions reduce the risk of CRI for patients with CVCs. However, these studies are limited by some methodological problems, which can result in bias risk. For example, Zhao et al concluded that ethanol lock is effective in reducing the incidence of CRBSI in hemodialysis patients[13]. However, in their meta-analysis, the majority of participants in the included studies were not hemodialysis patients. Zhang et al[14] pooled all of the data directly in their meta-analysis and did not distinguish the types of control used in each domain. Furthermore, a decision regarding the use of ethanol locks should be based on the sustainability of catheters and potential adverse events, which was not reported fully in either of these two meta-analyses[13,14]. In this case, we believe that it is still necessary to carry out studies in this field. Thus, to further clarify the efficacy and safety of ethanol locks for the prevention of CRI, we conducted this systematic review and meta-analysis based on these existing RCTs.

Materials and methods

Protocol and registration

This protocol has been registered in PROSPERO (http://www.crd.york.ac.uk/PROSPERO/) under registration number CRD42015027833.

Eligibility criteria

Type of study

Any relevant RCTs were included. For studies with the same or overlapping data by the same authors, the most appropriate studies with the largest number of cases or most recent publication dates were selected.

Participants

The participants were adults and children with a tunneled or nontunneled CVC as vascular access, regardless of the type of disease.

Type of interventions

Ethanol lock solutions were used in the intervention group. Solutions were allowed to dwell rather than simply being flushed through the catheter. A control condition (e.g., heparin locks) was used in the control group.

Outcomes of interest

The primary outcome was CRBSI (as defined by the study author). The secondary outcomes were exit site infection (defined as the development of purulent exudates or redness around the site not resulting from residual stitches), catheter dysfunction (defined as catheter blockage or persistent inadequate flow rate), removal of the catheter (defined as removal of the catheter for any reason before the end of prophylactic treatment), catheter thrombosis (defined as thrombosis or the need for thrombolytic therapy or removal of the catheter because of thrombosis), and all-cause mortality and adverse events as reported by the study author. Incidence was presented as the number of episodes per catheter-day.

Information sources and search

We systematically performed an electronic search of PubMed, the Cochrane Library, EMBASE (via the Embase.com platform), Sciences Citation Index (via the Web of Knowledge platform), the Chinese Biomedical Literature Database and the Chinese Digital Journals Full-text Database from their inception to March 2018 with no language restrictions. In addition, we searched unpublished theses and dissertations via the Conference Proceedings Citation Index, China Proceeding of Conference Full-text Database, China Doctoral Dissertation Full-text Database and China Master’s Theses Full-text Database. Relevant systematic reviews and meta-analyses from these databases were identified, and their bibliographies were scrutinized for further relevant trials, as were those of the RCTs included in the review. The search method included relevant text words and medical subject headings related to ethanol, infection, CVC and RCT. The exact search strategy used in the PubMed database is provided as an example in S1 text.

Study selection

Literature search results were imported into ENDNOTE X7 literature management software. Two authors independently reviewed the title, abstract or descriptors of the identified studies and excluded studies that clearly did not meet the inclusion criteria. After excluding duplicate and apparently irrelevant studies, the full text of the remaining studies was reviewed to assess eligibility for inclusion. Any disagreements were resolved by discussion or by seeking an independent third opinion. Excluded trials and the reason for their exclusion were listed and examined by a third reviewer.

Data collection process and data items

Two authors independently extracted the data from each study using a standardized data extraction checklist, which included study characteristics (e.g., first author’s name, publication year, journal, country where the study was conducted), characteristics of the study subjects (e.g., type of disease, number of participants, age, sex distribution), characteristics of the catheter (e.g., type of catheters, number of catheters, site of catheter insertion), interventions details (e.g., type of lock solutions, patient involvement, number of catheter days), outcome variables (e.g., number of episodes) and any additional prophylactic measures used that may have affected outcomes (e.g., catheter care). Outcomes were extracted preferentially by intention to treat (ITT) at the end of follow-up. Quantitative data were extracted to calculate effect sizes. Data on effect size that could not be obtained directly were recalculated when possible. Any discrepancy was resolved by consensus.

Risk of bias within individual studies

Two authors independently evaluated the methodological quality of the included studies for major potential sources of bias using the Cochrane Collaboration’s risk of bias tool[15], which includes the method of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. We evaluated the methodological quality of each study by rating each criterion as low, high or unclear risk of bias. Any disagreements were resolved through discussion with another reviewer if needed.

Statistical analysis

Review Manager Software (RevMan 5.3) was used for meta-analysis. We assessed clinical and methodological heterogeneity by carefully examining the characteristics and design of the included trials. The I2 statistic was used to assess heterogeneity among the studies, and values over 50% were considered to represent high heterogeneity. A fixed-effects model was used to pool the results unless significant heterogeneity was observed (I2> 50%), which required a random-effects model. All of the variables in the included studies were dichotomous data, so we used an odds ratio (OR) with a 95% confidence interval (CI) to analyze the effect size of the studies. Subgroup analysis was planned to assess the potential sources of heterogeneity (e.g., type of disease, type of catheter). We described the results of the original studies if the data could not be extracted to calculate the total effect.

Results

Study selection

Fig 1 presents a flow diagram illustrating the study selection process. The electronic searches identified 128 studies, of which 45 duplicates were excluded by Endnote software and 57 articles were clearly not relevant after the first screening. The full text of twenty-six studies was retrieved in-depth consideration, and 17 studies were excluded for the following reasons: multiple publications (n = 2), non-RCTs (n = 2), ineligible interventions (n = 4), nonassessment of outcomes of interest (n = 1), unavailable conference papers (n = 7) and unavailable full text (to date, we have been unable to obtain more information about this study although we have contacted the authors). Finally, 9 studies[1624] were included in our systematic review. References cited in published original and review papers were examined, and no further studies were found.

<h2>Flow diagram of included and excluded studies.</h2>
Fig. 1.

Flow diagram of included and excluded studies.


Characteristics of the included studies

The characteristics of the studies included in the systematic review are presented in Table 1. Of these included studies, two were performed in Australia[18,21], two in China[19,20], two in the Netherlands[17,22], one in the USA[24], one in France[23] and one in New Zealand[16]. The combined sample size across the 9 included studies was 2451 participants with a total of 3235 catheters[1624]. The patient samples in the included studies were variable. Three included hematology patients[16,17,21], three included hemodialysis patients[1820], one focused on pediatric oncology patients[22], one comprised parenteral nutrition patients[24], and one comprised renal-replacement therapy and plasma exchange patients[23]. All studies randomized patients to ethanol lock solutions, which were compared to either heparin or 0.9% NaCl. The concentration of the lock solutions used in individual studies is presented in S1 Table. In the studies we reviewed, various ethanol lock procedures were used (Table 2). Lock volume ranged from 1.5 to 3.3 ml. Lock dwell time varied among the studies, ranging from 2 minutes to 48 hours. In these studies, the most common catheters used were tunneled catheters, which were employed in 6 trials[1618,2022]. The location of the dialysis catheter was reported in 8 trials[1623], with the majority being inserted in the internal jugular and subclavian veins (S1 Table). The criteria used for CRBSI diagnosis were detailed in 8 trials[1618,2024]. In these studies, diagnostic criteria provided by different organizations were used. However, all criteria used for CRBSI diagnosis are based on laboratory-confirmed results. Additionally, catheter care is of crucial importance to patients using intravascular catheters. Only four studies[16,18,20,23] described catheter care procedures. Cleaning the catheter site and changing the dressing at each use appeared to be the most common type of catheter care.

Tab. 1.

Characteristic of the included studies.

<h2>Characteristic of the included studies.</h2>
Tab. 2.

Intervention protocols of the included studies.

<h2>Intervention protocols of the included studies.</h2>

Methodological quality of the included studies

Table 3 shows the quality assessment of the studies in this systematic review. All 9 included studies[1624] were randomized, but only six[1618,20,22,24] specified the method of randomization. Four studies[1618,22] depicted the allocation concealment, while the other studies did not reference whether any allocation concealment process was used. Three trials[17,22,24] blinded patients, personnel and outcome assessors. The patients and personnel providers alone were blinded in 2 trials[16,23]. Five studies reported withdrawals[16,17,20,22,23], and the remainder had no apparent dropouts. Intention to treat (ITT) was performed for all patients.

Tab. 3.

Methodological quality of the included studies.

<h2>Methodological quality of the included studies.</h2>

Meta-analysis

Ethanol vs heparin

CRBSI. A total of 7 trials[16,1822,24] (615 participants, 615 catheters) reported this outcome, but we were unable to include the study conducted by Yang[19] in our analysis because of missing data for catheter days; consequently, only 6 studies[16,1922,24] were included in the data pooling. The fixed-effects model was used because heterogeneity was not evident among these studies (P = 0.15, I2 = 38%). A statistically significant difference was observed (OR = 0.53, 95% CI 0.34, 0.82, P = 0.004), which indicated that ethanol lock solutions were more effective in reducing CRBSI when compared to heparin alone (Fig 2).

<h2>CRBSI per 1000 catheter days for trials that compared ethanol locks with heparin.</h2>
Fig. 2.

CRBSI per 1000 catheter days for trials that compared ethanol locks with heparin.


Exit site infection. Four studies[16,18,20,21] involving 230 participants (230 catheters) were included in this comparison. The fixed-effects model was applied because no significant heterogeneity was found (P = 0.89, I2 = 0%). The pooled analysis of these studies indicated that there was no significant difference between the two groups (OR = 0.88, 95% CI 0.28, 2.81, P = 0.83) (S1 Fig).

Catheter dysfunction. Four studies[18,19,20,22] reported this outcome, but we were unable to include the study conducted by Yang[19] in our analysis because of missing data for catheter days; therefore, only 3 studies[18,20,22] (388 participants, 388 catheters) were included in the data pooling. The fixed-effects model was used because heterogeneity was low among these studies (P = 0.34, I2 = 8%). No significant difference was observed between the groups (OR = 0.73, 95% CI 0.33, 1.62, P = 0.43) (S2 Fig).

Catheter removal. Two studies[16,22] involving 371 patients with 371 catheters were entered into the analysis of the effects of intervention on catheter removal. The fixed-effects model was used because the heterogeneity test showed an I2 of 0% among studies. No significant difference was observed between the groups (OR = 0.70, 95% CI 0.38, 1.28, P = 0.25) (S3 Fig).

Thrombosis. Four studies[16,18,21,22] involving 505 patients with 505 catheters contributed to the analysis of thrombosis. There was no heterogeneity among the trials (P = 0.48, I2 = 0%); therefore, we used the fixed-effects model for the pooled estimate. The pooled data showed that the occurrence of thrombosis was not significantly different between the groups (OR 0.96, 95% CI 0.21, 4.42, P = 0.96) (S4 Fig).

Mortality. Four studies[16,20,22,24] involving 441 patients reported mortality. A fixed-effects model was applied because no statistical heterogeneity was indicated (P = 0.92, I2 = 0%). The results of the meta-analysis showed that there was no significant difference between ethanol and heparin (OR 0.58, 95% CI 0.16, 2.02, P = 0.39) (S5 Fig).

Ethanol VS 0.9% NaCl

CRBSI. Two studies[17,23] involving 1836 participants with 2620 catheters reported this outcome. There was no heterogeneity among the trials (P = 0.42, I2 = 0%); therefore, we used the fixed-effects model for the pooled estimate. The pooled analysis of these studies indicated that there was no significant difference between the two groups (OR 0.74, 95% CI 0.43, 1.28, P = 0.28) (S6 Fig).

Mortality. Two studies[17,23] involving 1836 participants were included in this comparison. A fixed-effects model was applied because no statistical heterogeneity was indicated (P = 0.52, I2 = 0%). No significant difference was observed between ethanol and 0.9% NaCl (OR = 0.95, 95% CI, 0.78, 1.17, P = 0.64) (S7 Fig).

Sensitivity analyses

To assess the robustness of the conclusions, a sensitivity analysis was conducted to reanalyze the effect of ethanol locks on the primary outcome when expressed as episodes per patient. A total of 7 trials[16,1822,24] including 615 patients were included in the analysis. The pooled results showed a statistically significant difference between the two groups in favor of ethanol (OR = 0.46, 95% CI 0.29, 0.73, P = 0.001) (Fig 3). In addition, in the trial by Schoot et al[22], the participants were pediatric patients, which differed from the other six studies[16,1821,24]. Therefore, we excluded this study to perform the sensitivity analysis to assess the robustness of the conclusions to the quality of the data. After the sensitivity analysis, the results were unchanged, and there was still a statistically significant difference in CRBSI between the groups. No significant difference was observed between the two groups in terms of catheter dysfunction (OR = 0.56, 95% CI 0.23, 1.36, P = 0.20), thrombosis (OR = 0.63, 95% CI 0.10, 4.03, P = 0.62) and mortality (OR = 0.69, 95% CI 0.11, 4.42, P = 0.70). We did not recalculate effect sizes for catheter removal in this analysis due to the small number of studies that examined this outcome.

<h2>CRBSI per patient for trials that compared ethanol locks with heparin.</h2>
Fig. 3.

CRBSI per patient for trials that compared ethanol locks with heparin.


Adverse events

A summary of the adverse events reported in the included trials is presented in Table 4. There were only two trials[23,24] that claimed no adverse effects related to ethanol. The most commonly reported adverse events among the ethanol therapies were transient reactions, such as facial flushing, nausea/vomiting, dizziness/drowsiness and altered taste, which usually subsided in a few days. Sanders et al[16] reported that one patient in the ethanol group experienced an episode of dyspnea immediately after the first treatment and withdrew from the study. Slobbe et al[17] reported that one patient in the ethanol group had syncope shortly after flushing the first lock solution, but no further adverse effects occurred in this particular patient during subsequent ethanol lock procedures. Additionally, no life-threatening adverse events were observed.

Tab. 4.

Adverse events reported in the included trials.

<h2>Adverse events reported in the included trials.</h2>

Discussion

This meta-analytic review provided a quantitative summary of the currently available RCTs assessing the efficacy and safety of ethanol lock solutions for patients with CVC.

Summary of the results

Based on data from 7 RCTs[16,1822,24] that compared ethanol lock therapy to the current standard of care with heparin, the combined results showed a statistically significant effect size for CRBSI; however, there were no statistically significant differences between the two groups in other outcomes, such as exit site infection, catheter dysfunction, catheter removal, thrombosis, and mortality. In addition, in this meta-analysis, 2 studies[17,23] assessed the effect of ethanol compared with 0.9% NaCl locks. The pooled data showed a downward trend in the rate of CRBSI; however, this trend did not reach statistical significance. The results of the sensitivity analyses that excluded trials of pediatric patients showed broad agreement with the main analyses. On the whole, our results are in accordance with previously published systematic reviews [13,14,25,26]. In this case, our study adds to these previous efforts by providing an RCT-based confirmation of the efficacy of ethanol lock solutions for decreasing CRBSI.

As described in detail previously, CRI results from the migration of skin organisms along the catheter into the bloodstream or the contamination and colonization of catheter lumens[27]. Prevention strategies are directed at decreasing the growth and adherence of pathogens to the catheter hub and surface [27]. In vitro studies have demonstrated the efficacy of ethanol as a lock solution for the eradication of various pathogens that commonly cause CRBSI and for the prevention of biofilm formation[28,29]. Exit site infections are an additional cause of morbidity in patients with CVCs and may contribute to the pathogenesis of CRBSI [30]. In the studies included in our meta-analysis, a low incidence of exit site infections was observed with no difference between the ethanol lock group and heparin group, as expected.

It is notable that with the accumulation of studies supporting the efficacy of ethanol lock prophylaxis for CRBSI, concern has been raised regarding the particular risk of thrombosis with the ethanol lock solution. Ethanol appears to possess intrinsic anticoagulant activity. In some clinical practices, ethanol has been used as an anticoagulative agent and described as a substitute for heparin to maintain catheter patency[31,32]. In our study, there was no significant difference in the occurrence of thrombosis between the two arms.

Catheter integrity after ethanol lock exposure is another topic of interest in this field. In vitro studies have demonstrated that ethanol has a negligible impact on the mechanical properties of catheters[33,34]. In the current meta-analysis, no statistically significant effects were observed from the pooling data on catheter dysfunction and catheter removal. Whereas Mermel et al interpreted the literature as suggesting that the use of ethanol locks may be associated with catheter damage[35]. One explanation is that their finding on this problem was largely based on retrospective studies and qualitative analysis.

All-cause mortality was not affected by ethanol lock therapy. No significant difference was detected when comparing ethanol with heparin or 0.9% NaCl. Adverse events were described in the meta-analysis. Generally, the incidence of adverse reactions was tolerable across all included studies.

In this meta-analysis, although a lower incidence of CRBSI was observed in preventive ethanol locks when compared to 0.9% NaCl, the difference was nonsignificant. The minimal impacts may be explained by the small number of studies included in this comparison and the low event rates. In addition, for practical reasons, the duration of ethanol locks was short. In Slobbe et al’s study [17], they used a lock time of 15 minutes daily per catheter lumen. Souweine et al’s ethanol lock dwell time was only 2 minutes [23]. In other studies [16,1822,24], the dwell time was at least 2 hours.

Limitations

To achieve high internal validity, we included only RCTs in our exploration of the effects of ethanol lock solutions for patients with CVC. The review was conducted according to the prespecified protocol, which has been registered in PROSPERO. However, as is the case with all systematic reviews, several important limitations should be noted.

First, the reporting of the included studies themselves was incomplete. The majority of the studies failed to specify the method of randomization, use appropriate allocation concealment procedures, and ensure blinding of trial participants; these represent significant methodological limitations that may have biased the results.

Second, there was significant heterogeneity within the trials. For example, ethanol dwell times varied from 2 minutes to 48 hours. However, given the small number of eligible studies, we did not perform meaningful subgroup analysis, which is important given the heterogeneity of the study. We propose the need for further studies to explore the preventive effect and safety parameters of ethanol at different dwell times, if possible. Admittedly, with only seven small trials, it is difficult to use techniques such as funnel plots to examine the possibility of publication bias.

Moreover, in our meta-analytic review, no data were available regarding adverse reactions associated with long-term use of ethanol locks, which may occur when they are used for the prevention of CRBSI. The major reason may be the relatively short duration of follow-up of the included studies. It would be preferable to address this type of research question using long-term prospective studies.

Conclusion

Ultimately, despite these weaknesses, our quantitative literature review of RCTs provides clear support for the efficacy of ethanol lock solutions as a promising option for the prevention of CRBSI in patients with CVC. However, more attention should be paid to the uniformity of the ethanol lock procedure and toxic effects after long-term ethanol lock exposure.

Supporting information

S1 Text [pdf]
Search strategy used in PubMed.

S2 Text [doc]
PRISMA 2009 checklist.

S1 Table [xls]
Characteristic of the included studies.

S1 Fig [tif]
Effect sizes of ethanol locks on exit site infection compared to heparin.

S2 Fig [tif]
Effect sizes of ethanol locks on catheter dysfunction compared to heparin.

S3 Fig [tif]
Effect sizes of ethanol locks on removed catheters compared to heparin.

S4 Fig [tif]
Effect sizes of ethanol locks on thrombosis compared to heparin.

S5 Fig [tif]
Effect sizes of ethanol locks on mortality compared to heparin.

S6 Fig [tif]
Effect sizes of ethanol locks on CRBSI compared to 0.9% NaCl.

S7 Fig [tif]
Effect sizes of ethanol locks on mortality compared to 0.9% NaCl.


Zdroje

1. Rotstein C, Brock L, Roberts RS. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer patients. Infect Control Hosp Epidemiol. 1995;16:451–458. 7594391

2. Coyle VM, McMullan R, Morris TC, Rooney PJ, Hedderwick S. Catheter-related bloodstream infection in adult haematology patients: catheter removal practice and outcome. J Hosp Infect. 2004;57:325–331. doi: 10.1016/j.jhin.2004.04.007 15262394

3. Crispin A, Thul P, Arnold D, Schild S, Weimann A. Central venous catheter complications during home parenteral nutrition: a prospective pilot study of 481 patients with more than 30,000 catheter days. Onkologie. 2008;31:605–609. doi: 10.1159/000162286 19145093

4. Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S, et al. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol. 2002; 23:716–720. doi: 10.1086/501999 12517012

5. Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med. 2006;34:2084–2089. doi: 10.1097/01.CCM.0000227648.15804.2D 16763511

6. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63:124–132. doi: 10.1016/j.jhin.2005.12.016 16621137

7. Zacharioudakis IM, Zervou FN, Arvanitis M, Ziakas PD, Mermel LA, Mylonakis E. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59:1741–1749. doi: 10.1093/cid/ciu671 25156111

8. Snaterse M, Rüger W, Scholte Op Reimer WJ, Lucas C. Antibiotic-based catheter lock solutions for prevention of catheter-related bloodstream infection: a systematic review of randomised controlled trials. J Hosp Infect. 2010;75:1–11. doi: 10.1016/j.jhin.2009.12.017 20227787

9. Taylor JE, Tan K, Lai NM, McDonald SJ. Antibiotic lock for the prevention of catheter-related infection in neonates. Cochrane Database Syst Rev. 2015; CD010336. doi: 10.1002/14651858.CD010336.pub2 26040840

10. Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007;31:302–305. doi: 10.1177/0148607107031004302 17595439

11. Kayton ML, Garmey EG, Ishill NM, Cheung NK, Kushner BH, Kramer K, et al. Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. J Pediatr Surg. 2010;45:1961–1966. doi: 10.1016/j.jpedsurg.2010.05.014 20920713

12. Pieroni KP, Nespor C, Ng M, Garcia M, Hurwitz M, Berquist WE, et al. Evaluation of ethanol lock therapy in pediatric patients on long-term parenteral nutrition. Nutr Clin Pract. 2013;28:226–231. doi: 10.1177/0884533612468009 23232749

13. Zhao T, Liu H, Han J. Ethanol lock is effective on reducing the incidence of tunneled catheter-related bloodstream infections in hemodialysis patients: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50:1643–1652. doi: 10.1007/s11255-018-1855-4 29667048

14. Zhang P, Lei JH, Su XJ, Wang XH. Ethanol locks for the prevention of catheter-related bloodstream infection: a meta-analysis of randomized control trials. BMC Anesthesiol. 2018;18:93. doi: 10.1186/s12871-018-0548-y 30041610

15. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. doi: 10.1136/bmj.d5928 22008217

16. Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008;62:809–815. doi: 10.1093/jac/dkn284 18621987

17. Slobbe L, Doorduijn JK, Lugtenburg PJ, El Barzouhi A, Boersma E, van Leeuwen WB, et al. Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS One. 2010;5:e10840. doi: 10.1371/journal.pone.0010840 20520776

18. Broom JK, Krishnasamy R, Hawley CM, Playford EG, Johnson DW. A randomised controlled trial of heparin versus ethanol lock therapy for the prevention of catheter associated infection in haemodialysis patients—the HEALTHY-CATH trial. BMC Nephrol. 2012;13:146. doi: 10.1186/1471-2369-13-146 23121768

19. Yang JF, Liu Hong, Gao M, She LP, Zhang LP, Wang Y. Application of ethanol locks in maintenance hemodialysis patients with long-term catheter indwelling. Chin J Nosocomiol. 2013;23:318–319.

20. Sun XM. Ethanol versus Heparin Catheter Locks for Cuffed Central Venous Catheters in Hemodialysis Patients: A Single-center Randomized Controlled Trial. Dissertation, Southeast University. 2014. Available from: http://www.wanfangdata.com.cn/details/detail.do?_type=degree&id=Y2706576.

21. Worth LJ, Slavin MA, Heath S, Szer J, Grigg AP. Ethanol versus heparin locks for the prevention of central venous catheter-associated bloodstream infections: a randomized trial in adult haematology patients with Hickman devices. J Hosp Infect. 2014;88:48–51. doi: 10.1016/j.jhin.2014.06.007 25063013

22. Schoot RA, van Ommen CH, Stijnen T, Tissing WJ, Michiels E, Abbink FC, et al. Prevention of central venous catheter-associated bloodstream infections in paediatric oncology patients using 70% ethanol locks: A randomised controlled multi-centre trial. Eur J Cancer. 2015;51:2031–2038. doi: 10.1016/j.ejca.2015.06.126 26188849

23. Souweine B, Lautrette A, Gruson D, Canet E, Klouche K, Argaud L, et al. Ethanol lock and risk of hemodialysis catheter infection in critically ill patients. A randomized controlled trial. Am J Respir Crit Care Med. 2015;191:1024–1032. doi: 10.1164/rccm.201408-1431OC 25668557

24. Salonen BR, Bonnes SL, Vallumsetla N, Varayil JE, Mundi MS, Hurt RT. A prospective double blind randomized controlled study on the use of ethanol locks in HPN patients. Clin Nutr. 2018;37:1181–1185. doi: 10.1016/j.clnu.2017.05.009 28576557

25. Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics. 2012;129:318–329. doi: 10.1542/peds.2011-1602 22232307

26. Tan M, Lau J, Guglielmo BJ. Ethanol locks in the prevention and treatment of catheter-related bloodstream infections. Ann Pharmacother. 2014;48:607–615. doi: 10.1177/1060028014524049 24554477

27. Zhang J, li RK, Chen KH, Ge L, Tian JH. Antimicrobial lock solutions for the prevention of catheter-related infection in patients undergoing haemodialysis: study protocol for network meta-analysis of randomised controlled trials. BMJ Open. 2016;6:e010264. doi: 10.1136/bmjopen-2015-010264 26733573

28. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother. 2008;62:1024–1026. doi: 10.1093/jac/dkn291 18641034

29. Balestrino D, Souweine B, Charbonnel N, Lautrette A, Aumeran C, Traoré O, et al. Eradication of microorganisms embedded in biofilm by an ethanol-based catheter lock solution. Nephrol Dial Transplant. 2009;24:3204–3209. doi: 10.1093/ndt/gfp187 19383833

30. Oliver MJ, Callery SM, Thorpe KE, Schwab SJ, Churchill DN. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int. 2000;58:2543–2545. doi: 10.1046/j.1523-1755.2000.00439.x 11115089

31. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. JPEN J Parenter Enteral Nutr. 1987;11:507–508. doi: 10.1177/0148607187011005507 3116300

32. Johnston DA, Walker K, Richards J, Pennington CR. Ethanol flush for the prevention of catheter occlusion. Clin Nutr. 1992;11:97–100. 16839980

33. Crnich CJ, Halfmann JA, Crone WC, Maki DG. The effects of prolonged ethanol exposure on the mechanical properties of polyurethane and silicone catheters used for intravascular access. Infect Control Hosp Epidemiol. 2005;26:708–714. doi: 10.1086/502607 16156328

34. Bell AL, Jayaraman R, Vercaigne LM. Effect of ethanol/trisodium citrate lock on the mechanical properties of carbothane hemodialysis catheters. Clin Nephrol. 2006;65:342–348. doi: 10.5414/cnp65342 16724655

35. Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother. 2014;69:2611–2619. doi: 10.1093/jac/dku182 24891431


Článek vyšel v časopise

PLOS One


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy